Author:
van der Veer M S,de Weers M,van Kessel B,Bakker J M,Wittebol S,Parren P W H I,Lokhorst H M,Mutis T
Publisher
Springer Science and Business Media LLC
Reference9 articles.
1. Brenner H, Gondos A, Pulte D . Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521–2526.
2. Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Blade J et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011; 117: 6063–6073.
3. Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25: 3892–3901.
4. Hallek M, Pflug N . State of the art treatment of chronic lymphocytic leukaemia. Blood Rev 2011; 25: 1–9.
5. Ahmadi T, Chong EA, Gordon A, Leinbach L, Aqui NA, Nasda SD et al. Phase II trial of lenalidomide—dexamethasone—rituximab in relapsed or refractory indolent B-cell or mantle cell lymphomas resistant to rituximab. Blood (ASH Annual Meeting Abstracts) 2010; 116: 3962.
Cited by
95 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献